Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

specific

The reemergence of primary cutaneous diffuse large B-cell lymphoma, leg type after a period of remission.

15

Centers

16

Active Trials

—

Cancer Funding

Top Centers for Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type(15)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL
High-Volume Research Center
74.3
2
Siteman Cancer CenterSt. Louis, MO
NCI Comprehensive
Active Research Program
51.8
3
Mayo Clinic Comprehensive Cancer CenterRochester, MN
NCI Comprehensive
Active Research Program
51.8
4
The University of Chicago Medicine Comprehensive Cancer CenterChicago, IL
NCI Comprehensive
Active Research Program
51.8
5
Simmons Comprehensive Cancer Center UT Southwestern Medical CenterDallas, TX
NCI Comprehensive
Active Research Program
51.8
6
Laura and Isaac Perlmutter Cancer Center at NYU Langone HealthNew York, NY
NCI Comprehensive
Active Research Program
51.8
7
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH
NCI Comprehensive
Active Research Program
51.8
8
Moffitt Cancer CenterTampa, FL
NCI Comprehensive
Active Research Program
51.8
9
Roswell Park Comprehensive Cancer CenterBuffalo, NY
NCI Comprehensive
Active Research Program
51.8
10
The University of Arizona Cancer CenterTucson, AZ
NCI Comprehensive
Active Research Program
51.8
11
The University of Kansas Cancer CenterKansas City, KS
NCI Comprehensive
Active Research Program
51.8
12
Dartmouth Cancer CenterLebanon, NH
NCI Comprehensive
Active Research Program
51.8
13
University of Illinois Cancer CenterChicago, IL
Active Research Program
51.8
14
Cancer Center at IllinoisUrbana, IL
Active Research Program
51.8
15
Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ
Active Research Program
51.8

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →